Preclinical development of drug candidates for Alzheimer’s disease (AD) takes multiple different paths; animal models are indispensable tools to support diverse preclinical drug development programs. Charles River performs in-house evaluations employing several mouse models of AD using a range of up-to-date in vivo approaches with an emphasis on the translatability of findings in mice to changes that are observed in human patients.

This webinar highlights imaging as well as cognitive and physiological testing of these AD models and is useful for scientists engaged in drug discovery in the field of neurodegeneration.


  • Robert Hodgson, PhD, Director, Science R&D, Charles River
  • Maksym Kopanitsa, PhD, Head of Electrophysiology, Charles River